Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary

F. Abbas, P. T. Scardino

Research output: Contribution to journalArticlepeer-review

57 Citations (Scopus)


Neoadjuvant hormonal therapy (NHT) prior to radical prostatectomy has been advocated for downstaging of tumors and reducing the rates of positive surgical margins with the expectation that disease-free survival will be improved. Despite the apparent favorable impact on pathologic findings, randomized trials to date show no benefit of NHT in prostate specific antigen progression rates. Consequently, there is serious concern about the validity and biologic significance of the apparent downstaging and decreased rate of positive margins, and no evidence exists that there is improved time to progression and survival; therefore, the authors do not recommend NHT outside of a clinical trial.

Original languageEnglish
Pages (from-to)587-604
Number of pages18
JournalUrologic Clinics of North America
Issue number4
Publication statusPublished - 1996
Externally publishedYes


Dive into the research topics of 'Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary'. Together they form a unique fingerprint.

Cite this